Elevion's BTS Biogas Acquisition Shows Utilities Building Biomethane Platforms the Vertical Way

Elevion Group's agreement to acquire 100 percent of BTS Biogas is a statement about how serious European utilities intend to be in green gas. The CEZ-owned decarbonisation specialist is not buying a yield portfolio; it is buying an entire operating system for biomethane, combining nine Northern Italian plants with the engineering, construction and maintenance capabilities that built and run them. In a sector where value is created plant by plant through feedstock management, uptime and conversion expertise, owning the industrial capability matters as much as owning the assets, and this transaction, the group's largest in the sector to date, secures both in one move.

The scope of the deal, signed with the American parent BTS Bioenergy Europe, includes BTS Holdings Italy and its subsidiaries together with a portfolio of nine plants in Northern Italy, of which three are already operational and six are undergoing conversion. Once fully operational, the portfolio is expected to produce approximately 30 million standard cubic metres of biomethane per year. Set against Elevion's stated ambition of roughly 70 million standard cubic metres of annual renewable gas production by 2030, a single transaction delivers on the order of 40 percent of the group's end-decade target. The consideration was not disclosed.

The conversion profile of the portfolio is the tell for where Italian biomethane value sits. Six of the nine plants are being converted, reflecting the defining dynamic of the Italian market: an installed base of agricultural biogas plants built under earlier electricity incentive regimes is being upgraded to biomethane production, supported by dedicated national incentives for grid-injected renewable gas. Buyers who can execute those conversions technically, and then operate the upgraded plants reliably, capture the spread between a legacy biogas asset and a contracted biomethane producer. That is exactly the capability set BTS brings, including operation and maintenance experience on plants built with third-party technologies, which widens the serviceable market beyond its own installed fleet and gives Elevion a route to revenue across the entire value chain from plant engineering through construction to long-term operations.

The transaction lands in one of European clean energy's most consistently active M&A niches. Enerdatics' data records 164 bioenergy transactions in Europe since the start of 2023, with annual deal count holding remarkably steady at 58 in 2023, 46 in 2024 and 44 in 2025, and 16 already recorded in 2026 year to date, alongside disclosed value that peaked at around $4.5 billion in 2024. Where hydrogen deal-making has contracted sharply over the same period, biomethane has kept transacting through every phase of the rate and policy cycle, sustained by a fundamental advantage: the product drops into existing gas grids and industrial processes today, with no new demand infrastructure required.

The buyer universe in that market shows who Elevion is now competing with. Enerdatics' league table of European bioenergy acquirers since 2023 is led by dedicated platform aggregators and heavyweight capital: Goldman Sachs-backed Verdalia Bioenergy with five acquisitions, Copenhagen Infrastructure Partners and ENGIE with four each, and a following pack including DAH Gruppe, Kanadevia Inova, Suma Capital and Ancala Partners. The pattern is platform building through repeat small and mid-sized acquisitions rather than single large portfolio trades, because biomethane assets are inherently local, feedstock-bound and operationally intensive. Elevion's move fits the template while adding a differentiator most financial aggregators lack, namely in-house EPC, which converts the group from a buyer of plants into a manufacturer of them.

For CEZ, the strategic logic runs deeper than portfolio growth. Central European utilities face gas systems that must decarbonise without abandoning gas infrastructure, and biomethane is the molecule that squares that circle. An integrated platform spanning engineering, construction, ownership and operations gives the group optionality across the whole chain: build for its own account in Italy, service third-party owners, and eventually replicate the model across its home markets. For BTS's American parent, the sale monetises a mature European position at a moment when strategic demand for proven biomethane operators is demonstrably strong.

The forward signal is that European biomethane consolidation is entering its industrial phase. The first wave of the market was financial, with funds assembling plant portfolios for contracted cash flows. The wave now forming is capability-driven, with utilities and strategics acquiring the engineering and operating companies themselves, because the binding constraint on green gas growth is no longer capital but the ability to convert, build and run plants at scale. Sellers holding integrated developer-operators, rather than passive asset portfolios, are likely to find the deepest strategic interest and the fullest valuations.

Elevion's acquisition of BTS Biogas is therefore more than the group's biggest bioenergy deal. It marks the point where a major Central European utility chose to own the biomethane value chain outright, and it previews a consolidation cycle in which the scarce asset is not the plant but the platform that knows how to build one.

Ready to get deal-ready answers in seconds? Try Enerdatics Leap AI and access verified intelligence across M&A, financings, PPAs, projects, and energy market developments through natural language.